New study reveals a key player in lung cancer treatment resistance

This study discovered that an enzyme called APOBEC3B (A3B) influences both the development and resistance to EGFR-targeted therapy in lung cancer. This is important because understanding the impact of this enzyme on lung cancer will eventually enhance the effectiveness of targeted lung cancer treatments. This work was supported by a Stand Up To Cancer‐LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research.